MRK - Merck & Co., Inc.

NYSE - Nasdaq Real Time Price. Currency in USD
61.20
-0.27 (-0.44%)
As of 3:57PM EDT. Market open.
Stock chart is not supported by your current browser
Previous Close61.47
Open61.41
Bid61.19 x 2900
Ask61.20 x 1800
Day's Range60.64 - 61.62
52 Week Range52.83 - 66.41
Volume8,459,438
Avg. Volume11,166,479
Market Cap164.646B
Beta1.09
PE Ratio (TTM)106.25
EPS (TTM)0.58
Earnings DateJul 27, 2018
Forward Dividend & Yield1.92 (3.12%)
Ex-Dividend Date2018-06-14
1y Target Est69.06
Trade prices are not sourced from all markets
  • Merck (MRK) Presents New Data from Januvia Diabetes Studies
    Zacks4 hours ago

    Merck (MRK) Presents New Data from Januvia Diabetes Studies

    Merck (MRK) produces new data from two studies on type II diabetes medicine Januvia (sitagliptin), which supports the drug's clinical profile.

  • Reuters6 hours ago

    Clamour for GSK shingles shot points to bigger profits

    GlaxoSmithKline is facing "unprecedented" demand for its new shingles vaccine Shingrix, suggesting the product could be a bigger money-spinner than the company and analysts initially thought. GSK said it had increased deliveries significantly and was vaccinating people against shingles far faster than in the past, when Merck & Co's Zostavax was the only product available. "The arrival of Shingrix has been met with an unprecedented level of demand from patients and healthcare professionals," a spokesman said.

  • Reuters9 hours ago

    Clamour for GSK shingles shot points to bigger profits

    GlaxoSmithKline is facing "unprecedented" demand for its new shingles vaccine Shingrix, suggesting the product could be a bigger money-spinner than the company and analysts initially thought. GSK said it had increased deliveries significantly and was vaccinating people against shingles far faster than in the past, when Merck & Co's Zostavax was the only product available. "The arrival of Shingrix has been met with an unprecedented level of demand from patients and healthcare professionals," a spokesman said.

  • Business Wire9 hours ago

    FDA Accepts Supplemental Biologics License Application for Merck’s KEYTRUDA® (pembrolizumab) as Adjuvant Therapy in Advanced Melanoma

    Merck , known as MSD outside the United States and Canada, today announced that the U.S. Food and Drug Administration has accepted for standard review a new supplemental Biologics License Application for KEYTRUDA, Merck’s anti-PD-1 therapy, as adjuvant therapy in the treatment of patients with resected, high-risk stage III melanoma and granted a Prescription Drug User Fee Act , or target action, date ...

  • Business Wire2 days ago

    Merck Presents New Data from the Comparative Trials with Sitagliptin (CompoSIT) Clinical Trial Program with JANUVIA® (sitagliptin)

    Merck , known as MSD outside the United States and Canada, today announced new data from the Comparative Trials with Sitagliptin clinical trials with JANUVIA® .

  • The Wall Street Journal3 days ago

    [$$] Vaccine Expert Adel Mahmoud Took Up the World’s Problems

    Adel Mahmoud was lecturing his undergraduate global-health class at Princeton in 2014 when he broke down in tears. The Ebola outbreak was ravaging West Africa, and Dr. Mahmoud cried when he told the class he was going to do something to prevent diseases like Ebola from spreading. Students that day got to see the kind of person Dr. Mahmoud was, said his friend and Princeton colleague Jeremy Farrar.

  • Merck (MRK) Stock Up So Far This Year on Keytruda Strength
    Zacks3 days ago

    Merck (MRK) Stock Up So Far This Year on Keytruda Strength

    Merck's shares are up 8.4% this year driven by strong performance and positive regulatory updates related to its PD-1 inhibitor, Keytruda.

  • Is It Time To Sell Merck & Co Inc (NYSE:MRK) Based Off Its PE Ratio?
    Simply Wall St.3 days ago

    Is It Time To Sell Merck & Co Inc (NYSE:MRK) Based Off Its PE Ratio?

    I am writing today to help inform people who are new to the stock market and want to better understand how you can grow your money by investing in MerckRead More...

  • Reuters3 days ago

    U.S. medical device firm electroCore IPO price set at $15/shr

    U.S. medical device maker electroCore Inc's initial public offering is expected to price at $15 per share, Chief Executive Officer Frank Amato told Reuters on Thursday. ElectroCore, which is backed by the venture capital arm of Merck & Co, is set to debut on the Nasdaq on Friday under the ticker symbol "ECOR".

  • TheStreet.com4 days ago

    Novo Nordisk Stock Rises 4% Over 2 Sessions

    is riding the success of its experimental diabetes drug's positive test results, with the shares rising 1.65% Thursday to $46.40. The stock has been rising on a successful test that pitted Novo's oral semaglutide drug against the DDP-4 inhibitor Januvia from Merck & Co. and another Novo drug called Victoza, a once-a-week injectable pen used to regulate blood-sugar levels.

  • What GE’s stock being replaced by Walgreens in the Dow Jones Industrial Average may mean
    MarketWatch5 days ago

    What GE’s stock being replaced by Walgreens in the Dow Jones Industrial Average may mean

    General Electric will replace Walgreens Boots Alliance Inc., as one of the 30 components of the 122-year-old Dow Jones Industrial Average. Here’s what that means for one of the oldest equity benchmarks.

  • The Wall Street Journal5 days ago

    [$$] Wednesday's European Corporate Roundup

    A takeover bid by JCDecaux and a profit warning from U.K. housebuilder Berkeley are Wednesday’s corporate highlights in Europe.

  • Reuters6 days ago

    Latecomer Sanofi looks to catch next wave of cancer therapies

    Sanofi (SASY.PA) missed the boat on immune system-boosting cancer drugs. The French drugmaker has hired John Reed, the former top scientist at oncology market leader Roche (ROG.S) to head its group research operations. Dmitri Wiederschain, head of Sanofi's immuno-oncology research, acknowledged the company had failed to capitalise on the takeoff of immunotherapy - drugs that activate the body's immune system to attack tumour cells - in the early 2010s.

  • Better Buy: Celgene Corporation vs. Merck
    Motley Fool6 days ago

    Better Buy: Celgene Corporation vs. Merck

    Which of these oncology leaders will come out ahead?

  • In China, Baijiu and HPV Vaccines Have Something in Common
    Bloomberg7 days ago

    In China, Baijiu and HPV Vaccines Have Something in Common

    At first blush, HPV vaccines and Chinese rice wine don’t have much in common. For a start, shares in both have been on a tear. Kweichow Moutai is up 65 percent over the past 12 months, while Zhifei Biological, Merck & Co.’s exclusive sales agent in China, has risen 135 percent. The China Food and Drug Administration has accelerated approvals for new vaccines: While Merck’s Gardasil, which protects against four strains of human papilloma virus, took 1,421 days to get the nod, Gardasil 9, which protects against nine types of HPV, got the regulatory stamp from Beijing in just eight days.

  • How Is Merck Positioned Now?
    Market Realist7 days ago

    How Is Merck Positioned Now?

    Merck & Company (MRK) reported revenue of $10.0 billion in the first quarter, a rise of ~6% year-over-year, and GAAP (generally accepted accounting principles) EPS of $0.27 compared to net revenue of $9.4 billion and GAAP EPS of $0.56 in the first quarter of 2017.

  • InvestorPlace7 days ago

    The Blockchain Revolution Has Just Begun

    While cryptocurrencies like bitcoin are falling in value, the authors of the Blockchain Revolution insist its day has just begun. Don Tapscott and his son Alex, who co-authored the book, then founded the Blockchain Research Institute around it, are about to release an update, making this a good time to see where the revolution stands. A blockchain is simple in concept.

  • Investopedia7 days ago

    5 Drug Stocks With Fat Payouts

    Big Pharma is struggling to keep up with the rest of the market this year as tepid revenue, growth, the expiration of key patents, and the likelihood of the government imposing tighter cost controls hold back its performance prospects. Earlier this month, while the broader S&P 500 was yielding just 2%, the dividend yield on the big drug companies in the index was nearly a full percentage point higher at 2.9%.

  • 7 Perfect Dividend Stocks
    InvestorPlace10 days ago

    7 Perfect Dividend Stocks

    Dividend reinvestment is an amazingly powerful investment strategy. In fact, studies have shown that over a 20-year holding period, dividends account for 60% of all the gains in the S&P 500! Think about this for a minute. Since 1998, the S&P 500 would be around 60% lower if not for the benefits attributed to dividends.

  • Benzinga10 days ago

    Affimed Shares Slide On Updated Hodgkin Lymphoma Drug Combo Data

    Affimed NV (NASDAQ: AFMD ) shares were tumbling Friday after the release of updated data on its Hodgkin lymphoma treatment candidate. The metric investors are reacting to may be a decline in complete metabolic ...

  • Top Ranked Income Stocks to Buy for June 15th
    Zacks10 days ago

    Top Ranked Income Stocks to Buy for June 15th

    Top Ranked Income Stocks to Buy for June 15th

  • Pharma Stock Roundup: LLY/AZN Alzheimer's Drug Fails, MRK's Keytruda Wins Approvals
    Zacks10 days ago

    Pharma Stock Roundup: LLY/AZN Alzheimer's Drug Fails, MRK's Keytruda Wins Approvals

    Eli Lilly (LLY)/AstraZeneca (AZN) discontinue two late-stage studies on Alzheimer's disease candidate, lanabecestat. Merck's Keytruda gets FDA nod for two new indications.